Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lornoxicam
- Development stage
- Phase 4
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intramuscular
01
Overview
Lornoxicam (also known as chlortenoxicam) is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class. It exhibits analgesic (pain-relieving), anti-inflammatory, and antipyretic (fever-reducing) properties. Lornoxicam acts primarily by inhibiting cyclooxygenase enzymes COX-1 and COX-2 with high potency (IC50 values of 5 nM for COX-1 and 8 nM for COX-2), thereby reducing prostaglandin synthesis involved in pain and inflammation. It does not inhibit 5-lipoxygenase activity or leukotriene synthesis. Lornoxicam may also activate the opioid neuropeptide system to exert central analgesic effects. The drug is used to treat various types of pain—especially those associated with inflammatory joint diseases such as osteoarthritis—as well as postoperative pain and sciatica[1][2][3][4][5][6]. It is available in both oral and parenteral formulations.
- Brand names
- XefoXefocamXafonLorcamAcabel
- Other names
- chlortenoxicam氯诺昔康
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on lornoxicam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lornoxicam.